Efungumab, a monoclonal antibody exhibiting antifungal properties, specifically targets HSP 90 to inhibit a conformational alteration crucial for fungal survival. It is employed in investigations concerning invasive candidiasis (IC) [1].

Efungumab (2 mg/kg, i.p., once daily for three consecutive days) significantly reduced the average number of fungal colonies on the organs and increased the incidence of negative liver biopsy results in the CD1 mouse model of systemic Candida albicans infection [2].